Use of estradiol valerate in women with thin endometrium in ART cycles
Open Access
- 20 November 2025
- journal article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 17,p. 37-42
Abstract
Introduction . Patients with infertility often require the help of assisted reproductive technologies to solve their problem. Two thirds of failures in ART cycles are associated with insufficient endometrial receptivity. Aim . To evaluate the effectiveness of using estradiol valerate 2 mg (Progynova®) in women with thin endometrium in ART cycles. Materials and methods . The study included patients with a thin endometrium ≤ 7.0 mm according to the ultrasound examination (US) of the pelvic organs on the 10–14th day of the menstrual cycle (peak of luteinizing hormone (LH) in the blood or on the day of progesterone administration in the hormone replacement therapy cycle). Patients with a thin endometrium (n = 74) were divided into two groups: the first group (n = 43) – patients with chronic endometritis established by histological examination and immunohistochemistry (IHC); group 2 (n=31) – patients with a thin endometrium without chronic endometritis. All patients received estradiol valerate according to one of the following regimens: 4 mg estradiol valerate in a natural cycle from the moment the dominant follicle reached a diameter of 13 mm or 4 mg estradiol valerate from day 3 of the menstrual cycle. Results. Administration of estradiol valerate statistically significantly increased the endometrial thickness in women with thin endometrium (p < 0.05). The increase in endometrial thickness in patients of group 1 averaged 1.9279 mm, in patients of group 2 – 2.09 mm. The average endometrial thickness before treatment with estradiol valerate was 6.315 (4.7; 7.0) mm, after treatment – 8.311 (5.6; 11.0). 70 of 74 (94.6%) patients had an endometrial thickness of > 7 mm. Pregnancy in an IVF or PE cycle occurred in 44 patients with thin endometrium (62.5%) after treatment with estradiol valerate. Conclusions. The use of estradiol valerate in IVF and ET cycles increases the thickness of the endometrium and increases the frequency of pregnancy and live birth in patients with a thin endometrium.Keywords
This publication has 17 references indexed in Scilit:
- Walking on thin endometriumCurrent Opinion in Obstetrics and Gynecology, 2024
- A critical appraisal of studies on endometrial thickness and embryo transfer outcomeReproductive BioMedicine Online, 2023
- The thicker the endometrium, the better the neonatal outcomes?Human Reproduction Open, 2023
- Deciphering the endometrial niche of human thin endometrium at single-cell resolutionProceedings of the National Academy of Sciences, 2022
- Optimal endometrial thickness in fresh and frozen-thaw in vitro fertilization cycles: an analysis of live birth rates from 96,000 autologous embryo transfersFertility and Sterility, 2022
- Human implantation: The complex interplay between endometrial receptivity, inflammation, and the microbiomePlacenta, 2022
- Understanding the human endometrium in the 21st centuryAmerican Journal of Obstetrics and Gynecology, 2021
- Management of thin endometrium in assisted reproduction: a clinical practice guideline from the Canadian Fertility and Andrology SocietyReproductive BioMedicine Online, 2019
- The impact of a thin endometrial lining on fresh and frozen–thaw IVF outcomes: an analysis of over 40 000 embryo transfersHuman Reproduction, 2018
- Endometrial thickness of less than 7.5 mm is associated with obstetric complications in fresh IVF cycles: a retrospective cohort studyReproductive BioMedicine Online, 2018